Unicycive swings to Q1 FY26 net loss of $12.82 million; operating expenses rise 6% to $8.44 million

Unicycive Therapeutics

Unicycive Therapeutics

UNCY

0.00
  • Unicycive Therapeutics posted a net loss of USD 12.8 million, swinging from net income of USD 570,000 a year earlier.
  • Operating loss widened 6% to USD 8.44 million as operating expenses climbed 6% to USD 8.44 million.
  • General and administrative expense rose 17% to USD 6.83 million, while research and development expense fell 26% to USD 1.61 million.
  • Other results turned to expense of USD 4.39 million from income of USD 8.56 million on a USD 4.78 million change in fair value of warrant liability.
  • NDA resubmission for oxylanthanum carbonate was accepted as a Class II complete response; FDA set a PDUFA target action date of June 29, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-054708), on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.